Vaccine offers new cancer hope

Biotech firm PsiOxus Therapeutics, based at Milton Park, has launched the first clinical trial of its new anti-cancer vaccine, ColoAd1.

ColoAd1 is capable of destroying tumour cells at minute concentrations and can be injected into the bloodstream where it kills cancer cells while ignoring normal cells.

Chief executive John Beadle said: “This study could forge a path to a new treatment option for patients with metastatic cancer.”

Related links

click2find

About cookies

We want you to enjoy your visit to our website. That's why we use cookies to enhance your experience. By staying on our website you agree to our use of cookies. Find out more about the cookies we use.

I agree